

UPCOMING DART COHORT CLOSURES AS OF 29-APR-2025 6:10 AM
ENTIRE S1609 STUDY IS CLOSED TO ACCRUAL AS OF 03/15/23

| | | Up-coming | |
|---------------------------------|-------------|-----------|---------|
| | | Closure | Closure |
| # | COHORT Name | Date | Type |
| No up-coming closures to report | | | |

| Closure Type | # | COHORT NAME | TOTAL REGS. | REGS. | REGS. | REGS. | REGS. | REGS. | # of ACT. INSTs | # of CURR IRBs |
|--------------------|----|---|----------------|---------------------|--------------------|--------------------|--------------------|-------------------|-----------------------|----------------------|
| | | | | LAST 12 Month | LAST 6 Month | LAST 3 Month | LAST 30 DAYS | LAST 7 DAYS | | |
| Permanent Close | 1 | Epithelial tumors of nasal cavity, sinuses, nasopharynx | 7 | 0 | 0 | 0 | 0 | 0 | 4 | 1 |
| Permanent Close | 2 | Epithelial tumors of major salivary glands | 30 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 3 | Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 4 | Undifferentiated carcinoma of gastrointestinal (GI) tract | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 5 | Adenocarcinoma with variants of small intestine | 26 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 6 | Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 7 | Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary | 10 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 8 | Rare Pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma | 11 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 9 | Intrahepatic cholangiocarcinoma | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 10 | Extrahepatic cholangiocarcinoma and bile duct tumors | 10 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 13 | Non-epithelial tumors of the ovary | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 14 | Trophoblastic tumor | 3 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 15 | Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder | 1 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 16 | Cell tumor of the testes and extragonadal germ tumors | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 17 | Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis | 23 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 18 | Squamous cell carcinoma variants of the genitourinary (GU) system | 7 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 20 | Adenocarcinoma with variants of GU system (excluding prostate cancer) | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 21 | Odontogenic malignant tumors | 4 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 22 | Pancreatic neuroendocrine tumor (PNET) | 22 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 23 | Neuroendocrine carcinoma including carcinoid of the lung | 35 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 24 | Pheochromocytoma, malignant | 7 | 0 | 0 | 0 | 0 | 0 | | |

| Closure Type | # | COHORT NAME | TOTAL REGS. | REGS. LAST | REGS. LAST | REGS. LAST | REGS. LAST | REGS. LAST | # of ACT. INSTs | # of CURR IRBs |
|--------------------|----|---|----------------|---------------|---------------|---------------|---------------|---------------|-----------------------|----------------------|
| | | | | 12 Month | 6 Month | 3 Month | 30 DAYS | 7 DAYS | | |
| Permanent Close | 25 | Paraganglioma | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 26 | Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex | 21 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 27 | Desmoid tumors | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 28 | Peripheral nerve sheath tumors and NF1-related tumors | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 29 | Malignant giant cell tumors | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 30 | Chordoma | 11 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 31 | Adrenal cortical tumors | 23 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 32 | Tumor of unknown primary (Cancer of Unknown Primary; CuP) | 26 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 33 | Not Otherwise Categorized (NOC) Rare Tumors, after discussion with Study Chairs | 65 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 34 | Adenoid cystic carcinoma | 29 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 35 | Vulvar cancer | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 36 | MetaPLASTIC carcinoma (of the breast) | 19 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 37 | Gastrointestinal stromal tumor (GIST) | 12 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 38 | Perivascular epithelioid cell tumor (PEComa) | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 39 | Apocrine tumors/Extramammary Paget's Disease | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Temporary Close | 40 | Peritoneal mesothelioma | 18 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 41 | Basal cell carcinoma | 18 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 42 | Clear cell cervical cancer | 5 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 43 | Esthenioneuroblastoma | 7 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 44 | Endometrial carcinosarcoma (malignant mixed Mullerian tumors) | 25 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 45 | Clear cell endometrial cancer | 9 | 0 | 0 | 0 | 0 | 0 | | |

| Closure Type | # | COHORT NAME | TOTAL | REGS. | REGS. | REGS. | REGS. | REGS. | # of | # of |
|-----------------|----|---|-------|---------------|--------------|--------------|--------------|-------------|------------|-----------|
| | | | REGS. | LAST 12 Month | LAST 6 Month | LAST 3 Month | LAST 30 DAYS | LAST 7 DAYS | | |
| Temporary Close | 46 | Clear cell ovarian cancer | 25 | 0 | 0 | 0 | 0 | 0 | ACT. INSTs | CURR IRBs |
| Permanent Close | 48 | Gallbladder cancer | 22 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 51 | Angiosarcoma | 18 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 52 | High-grade neuroendocrine carcinoma | 21 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 53 | Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) | 19 | 0 | 0 | 0 | 0 | 0 | | |

DART ACCRUAL REPORT
ENTIRE S1609 STUDY IS CLOSED TO ACCRUAL AS OF 03/15/23

5

| Status | # | COHORT NAME | TOTAL REGS. | REGS. LAST 12 Month | REGS. LAST 6 Month | REGS. LAST 3 Month | REGS. LAST 30 DAYS | REGS. LAST 7 DAYS | # of ACT. INSTs | # of CURR IRBs |
|-----------------|----|--|----------------|------------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------------|-----------------------|----------------------|
| Permanent Close | 1 | Epithelial tumors of nasal cavity, sinuses, nasopharynx | 7 | 0 | 0 | 0 | 0 | 0 | 4 | 1 |
| Permanent Close | 2 | Epithelial tumors of major salivary glands | 30 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 3 | Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 4 | Undifferentiated carcinoma of gastrointestinal (GI) tract | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 5 | Adenocarcinoma with variants of small intestine | 26 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 6 | Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 7 | Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary | 10 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 8 | Rare Pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma | 11 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 9 | Intrahepatic cholangiocarcinoma | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 10 | Extrahepatic cholangiocarcinoma and bile duct tumors | 10 | 0 | 0 | 0 | 0 | 0 | | |
| Open | 11 | Sarcomatoid carcinoma of lung | 16 | 0 | 0 | 0 | 0 | 0 | | |
| Open | 12 | Bronchoalveolar carcinoma lung (a.k.a. adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma) | 8 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 13 | Non-epithelial tumors of the ovary | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 14 | Trophoblastic tumor | 3 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 15 | Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder | 1 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 16 | Cell tumor of the testes and extragonadal germ tumors | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 17 | Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis | 23 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 18 | Squamous cell carcinoma variants of the genitourinary (GU) system | 7 | 0 | 0 | 0 | 0 | 0 | | |
| Open | 19 | Spindle cell carcinoma of kidney, pelvis, ureter | 10 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 20 | Adenocarcinoma with variants of GU system (excluding prostate cancer) | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 21 | Odontogenic malignant tumors | 4 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 22 | Pancreatic neuroendocrine tumor (PNET) | 22 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 23 | Neuroendocrine carcinoma including carcinoid of the lung | 35 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 24 | Pheochromocytoma, malignant | 7 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 25 | Paraganglioma | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 26 | Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex | 21 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 27 | Desmoid tumors | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 28 | Peripheral nerve sheath tumors and NF1-related tumors | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 29 | Malignant giant cell tumors | 6 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 30 | Chordoma | 11 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 31 | Adrenal cortical tumors | 23 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 32 | Tumor of unknown primary (Cancer of Unknown Primary; CuP) | 26 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 33 | Not Otherwise Categorized (NOC) Rare Tumors, after discussion with Study Chairs | 65 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 34 | Adenoid cystic carcinoma | 29 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 35 | Vulvar cancer | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 36 | MetaPLASTIC carcinoma (of the breast) | 19 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 37 | Gastrointestinal stromal tumor (GIST) | 12 | 0 | 0 | 0 | 0 | 0 | | |

DART ACCRUAL REPORT
ENTIRE S1609 STUDY IS CLOSED TO ACCRUAL AS OF 03/15/23

6

| Status | # | COHORT NAME | TOTAL REGS. | REGS. | REGS. | REGS. | REGS. | REGS. | # of ACT. INSTs | # of CURR. IRBs |
|-----------------|----|---|----------------|---------------------|--------------------|--------------------|--------------------|-------------------|--------------------|--------------------|
| | | | | LAST 12 Month | LAST 6 Month | LAST 3 Month | LAST 30 DAYS | LAST 7 DAYS | | |
| Permanent Close | 38 | Perivascular epithelioid cell tumor (PEComa) | 17 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 39 | Apocrine tumors/Extramammary Paget's Disease | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Temporary Close | 40 | Peritoneal mesothelioma | 18 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 41 | Basal cell carcinoma | 18 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 42 | Clear cell cervical cancer | 5 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 43 | Esthenioneuroblastoma | 7 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 44 | Endometrial carcinosarcoma (malignant mixed Mullerian tumors) | 25 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 45 | Clear cell endometrial cancer | 9 | 0 | 0 | 0 | 0 | 0 | | |
| Temporary Close | 46 | Clear cell ovarian cancer | 25 | 0 | 0 | 0 | 0 | 0 | | |
| Open | 47 | Gestational trophoblastic disease (GTD) | 4 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 48 | Gallbladder cancer | 22 | 0 | 0 | 0 | 0 | 0 | | |
| Open | 49 | Small cell carcinoma of the ovary, hypercalcemic type | 7 | 0 | 0 | 0 | 0 | 0 | | |
| Open | 50 | PD-L1 amplified tumors (single-agent Nivolumab therapy) | 13 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 51 | Angiosarcoma | 18 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 52 | High-grade neuroendocrine carcinoma | 21 | 0 | 0 | 0 | 0 | 0 | | |
| Permanent Close | 53 | Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) | 19 | 0 | 0 | 0 | 0 | 0 | | |
| TOTAL | | | 798 | 0 | 0 | 0 | 0 | 0 | | |